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Summary 
The  cell surface glycoprotein CD8 functions as  a  coreceptor with  the  TCR  on cytotoxic T 
lymphocytes. Mutational  analysis of the binding site  of CD8 for MHC  class  I  predicted  that 
distinct surfaces of CD8 would interact with both the a2 and a3  domains of class I. Using a 
cell-cell adhesion assay,  we identified three residues Q115, D122, and E128 in the or2 domain 
of class  I  critical for interaction with CD8.  The side chains of these residues point towards a 
cavity formed by the 0tl/e~2  platform,  the or3 domain and  [32-microglobulin ([32m)  of class  I. 
These  residues  were predicted  to contact CD8 based on a bivalent  model of interaction be- 
tween one CD8o~/oL homodimer and two MHC  class I molecules. These results therefore pro- 
vide support for the model. 
M 
HC  class  I  molecules  are  highly polymorphic pro- 
teins  that bind antigenic  peptides  and present  them 
to T  cells.  The functional interaction  of cytotoxic T  cells 
with antigen-presenting cells requires the engagement oft 
cell receptor,  in concert with  CD8,  with  the  MHC/pep- 
tide  complex  (1,  2).  Following  a  large  body of evidence 
suggesting a central role of CD8 in T  cell signaling, activa- 
tion  and  thymic  selection,  much  interest  has  centered  on 
the characterization of interaction between various compo- 
nents involved in T  cell recognition  (3,  4).  It has become 
clear that  whereas  the  TCK  binds  to  the  or1  and  r  do- 
mains of a class  I-peptide  complex,  CD8 binds directly to 
the or3 domain (5-9). 
A  soluble form of CD8ot/ot homodimer was crystallized 
and  its  two  Ig-like  domains  were  found  to  share  many 
structural similarities with their Ig counterparts (10). Muta- 
tional  analysis  of CD8ot/ot  revealed  that  unlike  Ig mole- 
cules in which the surface containing the CDR loops is ex- 
clusively  used  to  recognize  antigen,  distinct  surfaces  of 
CD8ot/c~,  one  containing  the  CDR-like  loops  and  the 
other  comprised  of the  A  and  B  {3-strands,  interact  with 
class I (11). The discovery ofa non-CDR surface as an im- 
portant contact area on CD8ot led us to postulate that CD8 
interacted  not only with  the ~t3 domain but also with the 
or2 domain of class I. To test this hypothesis, we performed 
site-specific mutagenesis of class I and analyzed the mutants 
using  a  cell-cell  adhesion  assay  (12).  We  identified  three 
critical residues in the 0~2 domain,  two located underneath 
the  peptide-binding  floor and  one  on  a  nearby  loop,  all 
with the  side  chains pointing towards a  cavity (13).  Thus, 
CD8o~/ot appears to interact both with the or2 and o~3 do- 
main of MHC  class I. 
Materials and Methods 
Construction of Mutant  HLA-A2  cDNAs.  Site-specific  mu- 
tagenesis was performed as described  (14) using a cDNA template 
encoding HLA-A2010 (15). All mutations were confirmed by se- 
quencing a 430 bp PflMI/NdeI fragment of the HLA-A2 gene 
encoding the c~2 domain  (NdeI/SmaI fragment encoding cx3 in 
Q226A).  Fragments  were  inserted  into  corresponding  sites of 
wild type HLA-A2 in pBluescript  II. HLA-A2 mutants were then 
subcloned into NotI/SalI sites in the plasmid vector EBO-pLPP 
containing an hygromycin B resistance gene (16). 
Cells and Antibodies.  C1R is a B cell line that lacks endoge- 
nous HLA-A, B genes thus expresses virtually no class I products. 
Wild-type and mutant A2 cDNA constructs  were electroporated 
into CIR cells 960 IxF 250V (17). All A2 transfectants  (C1R-A2) 
were maintained in hygromycin B at 600-1,000 p,g/ml, depend- 
ing on levels of HLA-A2 expression.  CHO cells either transfected 
(MT8.02)  or mock transfected  (MT8.C13) with the CD8 c~-chain 
gene were provided by R. Salter  (University of Pittsburgh)  (12). 
MT8.02  and MT8.C13  CHO  cell lines  were grown in Ham's 
F12 medium lacking hypoxanthine  (JRH Biosciences,  Lenexa, 
KS) (6). High CD8 expression levels of MT8.02 were maintained 
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specific for HLA-A2 was used to stain all A2 transfectants,  mAb 
TP25.99 specific for the el3 domain of class I was provided by S. 
Ferrone (New York Medical College) (16).  Fluoresceinated goat 
anti-mouse IgG was  used  as a  secondary antibody. The  mAbs 
used  for  staining  CD8~x were  FITC-conjugated  OKT8  and 
Leu2a. 
Adhesion  Assay  Determining  Binding of HLA-A2  Mutants  to 
CD8.  The assay was modified from the method previously de- 
scribed (12).  Briefly, 0.3  X  10  s CD8 + or CD8-  CHO  cells per 
well were plated.  1  ￿  106  CIR. cells transfected with HLA-A2 
were  labeled with  a  fluorogenic esterase  substrate Calcein AM 
(Molecular Probes, Eugene, OR). The cells were incubated in 1 
ml PBS containing 10 p~g Calcein AM at 37~  for 30 rain. 3  ￿ 
10  s labeled C1R  cells were overlaid onto monolayers of CHO 
cells in triplicate. Bound C1R cells were lysed in 25  mM Tris/ 
0.1%  SDS after wash.  Readings were taken with a fluorescence 
spectrophotometer at 495  nm (excitation) and 525 nm (emission) 
the next day.  Measurement  of fluorescence intensity of the la- 
beled CIR  cells before addition to the plated CHO  cells indi- 
cated uniform labeling of C1R cells (data not shown). 
Binding Assay of Mutant CD8ee to Class L  The cell-cell bind- 
ing assay was performed as described (11).  Briefly, COS-7  cells 
firmly attached to a tissue culture dish were transfected using li- 
pofectamine  (Life  Technologies,  Inc.,  Grand  Island, NY)  with 
wild-type or mutant forms of CD8o~. CD8c~  transfectants  were 
tested for their ability to bind to the MHC class I + cell line UC 
(19). Since these UC cells were modified to constitutively express 
the firefly luciferase gene, the number of bound cells was deter- 
mined by measuring the amount of luciferase activity in the cell 
extract. Expression levels of CD8  in COS-7 cells were checked 
in  every  experiment  by  flow  cytometry  of cells  stained  with 
FITC-conjugated mAb OKT-8  and Leu2a.  Since the levels of 
cell surface expression varied slightly among wild-type and mu- 
tant forms of CD8,  the binding of UC cells was normalized ac- 
cording to the following formula: 100  ￿  % binding =  ([mutant 
binding -  vector binding]/mutant OKT8)/([wild-type binding - 
vector binding]/wild-type OKTS) (20). 
Results and Discussion 
To examine the effects of class I mutations on binding to 
CD8,  we  substituted  an  alanine  residue  in  several  areas 
within the 0~2 domain of class I.  The  majority of residues 
chosen  for mutagenesis was  based on  our  model of CD8 
and class I interaction (11). All positions were surface acces- 
sible  and  many  of them  well  conserved,  reasoning  that 
these residues are most likely to make contact with the class 
I  molecule without  rendering global structural alterations. 
Amino  acids Ql15  and D122  are on  the peptide-binding 
floor with  their  side  chains  pointing away from  the  cleft 
(Fig. 1 a). Residues K127, E128,  and D129  are located on 
the loop connecting [~-strands 3 and 4  ($3 and $4) whereas 
$123, T134,  and D137  are all on nearby $4. Another set of 
mutations,  D102,  Ll10,  and  Rlll  all  located  near  the 
junction of $1  and $2, were based upon another molecular 
docking model (21).  Residues E89 and E173  were chosen 
as  potential  controls  for  their  likely inability to  bind  to 
CD8 based on our model. Wild-type and mutant forms of 
an HLA-A2 cDNA were subcloned into an EBO  expres- 
sion vector and transfected into C1R cells that lack endog- 
enous HLA-A, B  genes  (17).  All CIR-A2  mutants except 
for D129  expressed high levels of HLA-A2 with mean flu- 
orescence  intensities ranging  from  90-110%  of the  wild- 
type transfectant (Fig. 1 b). 
The  A2  transfectants  were  tested  for binding to  CHO 
cells expressing the  human  CD8ci  gene,  using  a  cell-cell 
adhesion assay. As shown  in Fig. 2  a, fluorescence-labeled 
wild-type  transfectants  bound  to  the  CD8 +  CHO  cell 
monolayer  to  near  saturation.  The  binding  of HLA-A2 
C1R  transfectants  to the  CD8 +  CHO  cells was  mediated 
specifically by MHC  class I  and CD8  molecules since this 
interaction can be exclusively and completely inhibited by 
either anti-class I or anti-CD8 mAbs (5,  12). We included 
two  mutants,  A245V  and  Q226A  of HLA-A2 as negative 
controls since these mutations in the 0~3 domain were pre- 
viously shown to be responsible for negative CD8 binding 
phenotypes  (5,  6).  Neither  of these  two  mutant  transfec- 
tants bound to the CD8 + CHO  cells (Fig. 2, a and b). 
Mutations at Ql15, D122,  and E128 showed no specific 
binding to CD8  (Fig. 2, a and b). This effect can not be at- 
tributed  to  levels  of HLA-A2  expression  by  the  various 
transfectants,  since  expression  levels  of  the  non-binders 
were equal to or greater than at least one of the CD8 bind- 
ers (Fig. 1 b and data not shown). To exclude possible indi- 
rect effects on the o~3  domain by conformational changes, 
we stained all mutants with mAb TP25.99  that binds spe- 
cifically to the oL3 domain of class I where the critical CD8 
binding loop was located (22).  Staining of all mutants with 
TP25.99 was similar to the wild-type transfectant (data not 
shown).  These  results suggest  direct involvement of these 
three residues in contacting CD8 cx-chain. While E128 ap- 
peared critical in binding, mutations at nearby K127 or dis- 
tant E89 and E173 did not affect the interaction. Mutations 
$132A,  T134A,  and D137A  on  $4  did not  affect binding 
(Fig. 2, a and b), nor did the exposed junction near $1  and 
$2  (D102A,  L110A,  R111A,  and  D102A/RlllA),  indi- 
cating that much of other exposed areas on the o~2 domain 
of class  I  is  not  likely to  be  critical for  interacting  with 
CD8. Since our analysis did not score mutations that simul- 
taneously resulted in a loss of surface expression and a  re- 
duced affinity for CD8  (i.e., D129,  data not  shown),  the 
data resulted in description of only a group of critical resi- 
dues.  In cocrystals of human  growth  hormone  and  its re- 
ceptor, a few contact amino acids clustered in a central region 
accounted  for  85%  of the  binding  free  energy  resulting 
from the alanine substitutions whereas all peripheral residues 
only contributed to 15% of the binding free energy (23). 
To further define the A/B surface of CD8 that may con- 
tact  the  oe2  domain  of MHC  class  I,  we  mutated  several 
solvent accessible residues on the A, B, and G  13-strands of 
human  CD8  to  alanine.  Once  CD8  mutants were  gener- 
ated,  a  transient  cell-cell adhesion assay was  employed as 
described (11).  In this assay, COS  7  cells expressing CD8 
mutants were tested for their ability to bind to the class I + 
cell line UC  that carries a firefly luciferase gene.  Replace- 
ment of R4 with a  similarly positively-charged lysine also 
resulted in complete inhibition of binding (Fig. 3, p.  1279) 
(11).  Alanine  substitution  at  Q23  on  the  B  strand  had  a 
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Figure  1.  Positions of MHC class I variants and expression on C1R cell transfectants. (a) et-carbon backbone of the etl and et2 domains of class I 
(HLA-A2). The domains and the peptide-binding groove are shown as viewed from the top of the molecule. Closed circles indicate conserved residues, 
and open circles nonconserved. The figure is modified from Fig. 4 of reference number (37).  (b) Stable expression of wild-type and mutant HLA-A2 
molecules in CIR cells. Shown are representative flow cytometry profiles from one experiment. Expression levels were monitored in every assay, and 
samples were stained with HLA-A2-specific mAb MA 2.1  (18) plus fluoresceinated goat anti-mouse IgG as described (6). 
similar effect, suggesting that this residue may participate in 
the interaction as part of the R4/L25 surface of CD8. The 
effect of mutations  in  other positions  on binding ranged 
from moderately-affected (L8, E19, and T47) to unaffected 
(D9  and H106).  It appeared that only a small  number of 
residues on the CD8 A and B but not the G J3-strands were 
critical  to  the  interaction with  the  or2  domain  of MHC 
class I. 
Examination of  the crystal structure of HLA-A2 reveals a 
large open cavity on the molecular surface (Fig. 4, a and b). 
The cavity is composed of the 0Uot2 platform, the loops of 
the or3 domain and a part of J32m with the  CD8  contact 
residues all on one side of this cavity. About one-third of 
the underside of the 0tlot2 13-sheet constituting the floor of 
the  groove is  exposed to  this  space  (13).  Residues  Ql15 
and  D122  are  both located on  the  floor of the  peptide- 
binding groove with  their side  chains pointing down to- 
wards  this  cavity  (Fig.  4  a).  Residues  Ql15,  D122  and 
E128 are completely conserved in 22 human  (24,  25) and 
12 murine (26) sequences. Our results are supported by the 
observation that murine primary CD8 + T  cells responded 
more vigorously to  an  HLA-A2 hybrid with  the  murine 
et20t3 domain than with only the murine 0t3 domain (27). 
The impact of the or2 domain of class I on recognition by 
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CD8 +  T  cells  is  further supported by  a  recent  study in 
which CTL responses in human CD8 transgenic mice to an 
A2/k  b hybrid molecule (human etlet2 domain, murine 0t3 
domain)  were markedly enhanced compared to responses 
in nontransgenic mice. These results provide functional ev- 
idence for a second interaction site outside of the or3 do- 
main that is essential  for optimal coreceptor function (28). 
In experiments discounting the involvement of the or2 do- 
main  in  binding  CD8,  most positions  tested for binding 
were either polymorphic or on the upper faces of the etlcx2 
domains (5, 6). Interestingly, two of the three critical resi- 
dues in the or2 domain of class I found in this study were 
negatively charged whereas residue R4 on the lateral side 
of CD8 was positively charged. This charge complementa- 
rity coincides with that of the contact surface between the 
or3 loop of class I and the CDR-like regions of CD8, sup- 
porting a crucial role for electrostatic interactions between 
CD8 and class I molecules (6, 11). 
Previous  work  on  the  interaction  between  CD8  and 
MHC class I had implicated the importance of the CDR- 
like loops of CD8 and the or3 domain of class I (5, 20). Our 
results  extend this interaction to include the or2 domain of 
class I interacting with the A/B surface of CD8. A CD8ct/ 
ot homodimer would fit into the class I/J32m cavity through A  B  A24sv 
Q226~ ~ 
EBgA 
EI73A  i~ 
D102A  ._p 
L110A 
R !11A 
O102A RI11A  - 
~1  0115A 
DI22A 
K127A 
E128  A  ~--q 
S132A 
T 134A 
D137A  ,  ,  M  ,  .  ,  ,  ,  ,  ,  ,  ,  ￿9  , 
2Q  40  60  B0  100  120  140  160 
Binding  relative  to  wild  type  HLA-A2  (%) 
Figure  2.  Cell-cell adhesion assay determining bind- 
ing of MHC  class  I  to  CD8oL  (a)  Fluorescent micros- 
copy of labeled C1R cells expressing wild-type or mu- 
tant  class  I  variants  bound  to  a  monolayer  of CD8  + 
CHO  cells  (MT8.02)  (12).  (b)  Adhesion of C1R  cell 
transfectants expressing mutant class  I  to  either  CD8+ 
(closed,  MT8.02  line)  or  CD8-  CHO  cells  (open, 
MT8.C13  line)  (12).  A2  transfectants  were  grouped 
based on their locations on the surface of class I  mole- 
cule.  Results  from  three  experiments  were  averaged 
(E173A from two experiments) and were expressed rela- 
tive to wild-type binding. S132, T134, and D137 trans- 
fected C1R cells were grown in RPMI  1640 tissue cul- 
ture medium. Error bars represent SE.  For each mutant, 
2-6 repeated assays gave similar results, The binding assay 
was conducted in double blind fashion. D129A showed a 
significant loss of  binding (15-20% of  wild type), but due 
to  its  noticeable  toss of expression level  on  C1R  cells 
(75%  mean fluorescence intensity of wild  type),  results 
were not included in the figure. 
part of its CDR-like  loops and the entire A/B  binding  sur- 
face  from  one  monomer  (Fig.  4  a).  Given  this  alignment, 
one  CD8cx/o~  homodimer  could  interact  simultaneously 
with  two  symmetrically  related  HLA  molecules  (Fig.  4  b). 
Our results provide  support for this model in that the three 
critical  residues  in  the  0t2 domain  were predicted  to  inter- 
act with  CD8  based on the model.  Assuming  the model  is 
correct,  there are residues on ~2m that are likely to interact 
with CD8  as well. 
The  alignment  of CD8  with  class  l  has important impli- 
cations for the  function  of the  CD8ci/ot  molecule.  CD8  is 
Figure  4.  Models of mutations located on the  CD8ot/tx  homodimer 
and MHC class I molecules affecting interaction between the two mole- 
cules. Models were  generated by Quanta  (Polygen, Waltham, MA).  (a) 
The class I molecule is shown as viewed perpendicularly to the pseudo- 
dyad axis of the cr  domains. The al  and ix2 domains are at the top 
with the ~x2 helices in front. Directly underneath odor2 is the ~2m subunit 
(light blue).  Positions where substitution to an alanine led to complete in- 
hibition  of binding  are  in  red  (Ql15,  D122,  E128,  and  the  223-229 
loop).  Amino acids where  substitutions had minimal effects on binding 
are in green (E89, D102, Ll10, Rl11, K127, and E173). The open cavity 
on the surface of the MHC class I crystal is composed of the ci1~2 plat- 
form, the loops of  the or  domain and a part of ~2m. Another angle of this 
cavity is revealed in the right side view ofMHC  classs I in b. (b) Potential 
interactions between a single CD80e/a homodimer and two MHC class I 
molecules.  CD8  is rotated  90  ~ about its dimer axis and  the  CDR-like 
loops are facing down. The left and the right flanking MHC class I mole- 
cules are viewed perpendicularly to the (xloc2 pseudo-dyad with the cleft 
viewed end- and head-on, respectively. The molecules have been pulled 
apart to better display the interaction. Positions on CD8 that led to com- 
plete  inhibition or had minimal effects with  alanine substitutions are  in 
red and green, respectively. Positions on CD8 that led to inhibition with 
only the charge/size substitution are in dark blue (11). r 
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Figure 3.  Cell-cell  adhesion assay of mutant forms of CD8~ to MHC 
class I. Shown are data from three experiments expressed relative to wild- 
type binding. Error bars represent SE. A, B, C' and G [3-strands of  CD8ot 
span residues 3-12, 17-24, 45-51, and 102-113, respectively (10). 
likely to induce dimerization  of MHC  class  I.  It has been 
shown  that  cross-linking  class  I  led  to  signal  transduction 
(29-32).  Conversely,  the  dimerization  may  bridge  two 
TCRs interacting with class I molecules, and thus promote 
the capping of TCR  and facilitate  complex formation be- 
tween TCR  and associated signal molecules. Such a model 
was proposed for T  cell receptor,  CD4, and MHC  class II 
complexes based on the  finding that the  crystals of MHC 
class II molecules were dimers of dimers (33). 
The CD8 molecule exists as  either an or/or  homodimer 
or ot/[3 heterodimer.  Only the CD8ot/ot homodimer is ex- 
pressed on a subset of human NK cells and T  cell receptor 
~//B cells in the gut. Both forms are present on thymocytes 
and  peripheral  T  cells,  however,  the  ot/[3  heterodimer  is 
predominant.  The  heterodimer  could  also  be  bivalent  by 
analogy  with  growth  hormone  and  its  receptor  (23). 
Growth hormone interacts through two nonidentical bind- 
ing sites to nearly identical sites  on two hormone receptors. 
Another potential consequence of CD8 interaction with 
the et2 domain could be to influence the conformation of 
MHC  peptide  formed by the  or1  and  or2  domains.  Small 
conformation effects might affect TCR-peptide-MHC  in- 
teractions.  It has been shown that small changes in peptides 
can  significantly  alter  the  outcome  for  TCR  activation 
through differential  TCR  signaling (34,  35).  The require- 
ment  for  CD8  in  TCR  triggering  has  generally  been 
thought  to  result  from  increases  in  TCR-peptide-MHC 
avidity by interaction  of CD8  with the  et3  domain.  Sup- 
porting the notion that CD8 may be doing more than just 
increasing avidity solely through interaction with MHC,  a 
recent  paper  demonstrated  a  role  for CD8-TCR  interac- 
tion  in  modulating  TCR-ligand  interaction  (36).  Our 
work suggests the possibility of modulation of TCR-ligand 
interaction through CD8-class I et2 domain interaction. 
We thank R. Salter for MT8.C13 and MT8.02 CHO cells and advice on the cell-cell  adhesion assay; R. 
Simmons and M. Barr for technical assistance; L. Kieffer for critical reading of the manuscript; P. Creswell 
for CIR cells; P. Parham for HLA-A cDNA; S. Ferrone for TP25.99 mAb; J. Fisher for help with the prep- 
aration of the manuscript. J. Sun is a recipient of the Brown-Coxe Fellowship. 
This work was funded by a grant from the National Institutes of Health (P. B. Kavathas). D. J. Leahy is sup- 
ported by the Searle Scholars Program and a Junior Faculty Research Award from the American Cancer So- 
ciety. 
Address correspondence  to Dr. Paula Kavathas, Fitkin 617, Yale University  School of Medicine,  333 Cedar 
Street, New Haven, Connecticut 06520-8035. 
Received for publication  I6 May  1995 and in revised  form 24July  t995. 
References 
1. Dembic, Z., W. Haas, R. Zamoyska, J.R. Parnes,  M. Stein- 
metz, and H. von Boehmer. 1987.  Transfection of the CD8 
gene enhances T-cell recognition. Nature  (Lond.). 326:510- 
511. 
2.  Gabert,  J.,  C.  Langlet,  R.  Zamoyska, J.R.  Pames,  A.M. 
Schmitt-Verhulst,  and B.  Malissen.  1987.  Reconstitution of 
MHC class I specificity by transfer of the T ceU receptor and 
Lyt-2 genes.  Cell. 50:545-554. 
3. Janeway, C.A.  1992.  T  cell receptor signalling: high fives or 
hand clasps? Curt. Biol. 2:591. 
4.  Ledbetter, J.A., J.P.  Deans, A. Aruffo, L.S.  Grosmaire,  S.B. 
1279  Sun et al. 
5. 
6. 
Kanner, J.B.  Bolen,  and  G.L.  Schieven.  1993.  CD4,  CD8 
and the role of CD45 in T-cell activation.  Curr. Opin. Immu- 
nol. 5:334-340. 
Salter,  R.D.,  A.M.  Norment,  B.  P.  Chen,  C.  Clayberger, 
A.M.  Krensky, D.R.  Littman,  and P.  Parham.  1989.  Poly- 
morphism  in  the  or3  domain  of HLA-A molecules  affects 
binding to CD8. Nature (Lond.). 338:345-347. 
Salter,  R.D.,  R.J.  Benjamin,  P.K.  Wesley,  S.E.  Buxton, 
T.P.J.  Garrett,  C.  Clayberger,  A.M.  Krensky,  A.M.  Nor- 
ment, D.R. Littman, and P. Parham. 1990. A binding site for 
the T-cell co-receptor CD8 on the et3 domain of HLA-A2. Nature (Lond.). 345:41-46. 
7.  Aldrich, C.J., R.E. Hammer, S. Jones-Youngblood, U. Kos- 
zinowski, L. Hood, I. Stroynoski, andJ. Forman. 1991. Neg- 
ative and positive selection of antigen-specific cytotoxic T 
lymphocytes affected by the  0t3  domain of MHC  1 mole- 
cules. Nature (Lond.). 352:718-721. 
8.  Ingold, A.L., C. Landel, C. Knall, G.A. Evans,  and T.A. Pot- 
ter. 1991. Co-engagement of CD8 with the T cell receptor is 
required for negative selection. Nature (Lond.). 352:721-723. 
9.  Sherman,  L.A., S.V.  Hesse, M.J.  Irwin, D.  LaFace, and P. 
Peterson.  1992.  Selecting T  cell receptors with high affinity 
for self-MHC by decreasing the contribution of CD8.  Science 
(Wash.  DC). 258:815-818. 
10. Leahy, D.J., R. Axel, and W.A. Hendrickson.  1992.  Crystal 
structure of a soluble form of the human  T  cell coreceptor 
CD8 at 2.6 A resolution. Cell. 68:1145-1162. 
11. Giblin, P.A.,  D.J.  Leahy, J.  Mennone,  and  P.B.  Kavathas. 
1994.  The role of charge and multiple faces of the CD8cx/ot 
homodimer in binding to major histocompatibility complex 
class I  molecules: support for  a bivalent model.  Proc. Natl. 
Acad. Sci. USA. 91:1716-1720. 
12. Norment,  A.M.,  R.D.  Salter, P.  Parham,  V.H.  Engelhard, 
and  D.R.  Littman.  1988.  Cell-cell adhesion  mediated  by 
CD8 and MHC class I molecules. Nature (Lond.). 336:79-81. 
13. Saper, M.A., P.J. Bjorkman, and D.C. Wiley. 1991.  Refined 
structure of the human histocompatibility  antigen HLA-A2 at 
2.6 A resolution.J. Mol. Biol. 219:277-319. 
14. Kunkel,  T.A.  1985.  Rapid  and  efficient  site-specific mu- 
tagenesis without phenotypic selection. Proc. Natl.  Acad. Sci. 
USA. 82:488-492. 
15. Hogan, K.T., C.  Clayberger, E.J.  Bernhard,  S.F. Walk, J.P. 
Ridge, P. Parham, A.M. Krenski, and V.H. Engelhard. 1988. 
Identification by site-directed mutagenesis of amino acid resi- 
dues contributing to serologic and CTL-defined epitope dif- 
ferences  between  HLA-A2.1  and  HLA-A2.3. J.  Immunol. 
141 (7):2519-2525. 
16. Spickofsky, N., V.  Canfield, and R.  Margolskee. 1990.  Ex- 
pression libraries in epstein-barr virus shuttle vectors capable 
of stable episomal replication. DNA  and  Protein Engineering 
Techniques. 2(1):14-19. 
17. Storkus, W.J., D.N. Howell, R.D.  Salter, J.R. Dawson, and 
P.  Cresswell.  1987.  NK  susceptibility varies inversely with 
target cells class I HLA antigen expression.J. Immunol.  138(6): 
1657-1659. 
18. McMichael, A.J., P. Parham, N. Rust, and F. Brodsky. 1980. 
A monoclonal antibody that recognizes an antigenic determi- 
nant shared by HLA A2 and B17.  Human  Immunol.  1:121- 
129. 
19. Glassy, M.C., H.H. Handley, H. Hagiwara, and I. Royston. 
1983.  UC 729-6, a human lymphoblastoid B-cell line useful 
for  generating  antibody-secreting human-human  hybrido- 
mas. Pro& Natl. Acad. Sci. USA. 80:6327-6331. 
20.  Sanders, S.K., R.O.  Fox, and P. Kavathas.  1991.  Mutations 
in CD8 that affect interactions with HLA class I and mono- 
clonal anti-CD8 antibodies.J. Exp. Med.  174:371-379. 
21.  Langedijk, J.P.M.,  W.C.  Puijk, W.P. vanHoorn,  and R.H. 
Meloen.  1993.  Location of CD4  dimerization site explains 
critical role  of CDR3-1ike  region in  HIV-1  infection and 
T-cell activation and implies a model for complex of core- 
ceptor-MHC.J. Biol. Chem.  268:16875-16878. 
22.  Tanabe,  M.,  M.  Sekimata,  S.  Ferrone,  and  M.  Takiguchi. 
1992.  Structural and functional analysis ofmonomorphic de- 
terminants  recognized  by  monoclonal  antibodies  reacting 
with the HLA class I or3 domain.J. Immunol.  148:3202-3209. 
23.  Clackson, T., andJ.A. Wells. 1995. A hot spot of binding en- 
ergy in  a  hormone-receptor interface.  Science (Wash.  DC). 
267:383-386. 
24.  Cowan, E.P., M.L. Jelachich, W.E. Biddison, and J.E.  Coli- 
gan. 1987.  DNA sequence of HLA-A11: remarkable homol- 
ogy with HLA-A3 allows identification of residues involved 
in epitopes recognized by antibodies and T  cells. Immunoge- 
netics. 25:241-250. 
25.  Gussow, D., R.S. Rein, M. Ingeborg, W. de Hoog, G.H.A. 
Seemann, F.M. Hochestenbach, and H.L. Ploegh. 1987.  Iso- 
lation, expression, and the  primary structure  of HLA-Cwl 
and  HLA-Cw2  genes:  evolutionary aspects.  Immunogenetics. 
25:313-322. 
26. The evolution of MHC  class I genes.  1992.  In Immunology 
Today. Vol. 13. Elsevier, Cambridge, UK. 
27.  Newberg,  M.H.,  D.  Smith,  L.  Lacy,  and V.H.  Engelbard. 
1994.  Species specific T  cell recognition of both the o~2 and 
or3 domains of MHC class I and the role of CD8.J.  Cell Bio- 
chem. (Suppl.).  18D:344. 
28.  La  Face, D.M.,  M.K.  Vestberg, Y.  Yang,  R.  Srivastava,  J. 
DiSanto, N. Flomenberg, S. Brown, L.A. Sherman, and P.A. 
Peterson.  1995.  Human CD8  coreceptor regulation of HLA 
recognition by murine T cells. J. Exp. Med. In press. 
29.  Geppert, T.D., H. Nguyen, and P.E. Lipsky. 1992.  Engage- 
ment of class I major histocompatibility complex molecules 
by cell surface CD8 delivers an activation signal.  Eur. J.  Im- 
munol. 22:1379-1383. 
30.  Gilliland, L.K., N.A. Norris, L.S.  Grosmaire, S.  Ferrone, P. 
Gladstone, and J.A.  Ledbetter.  1989.  Signal transduction in 
lymphocyte activation through  crosslinking of HLA class I 
molecules. Human Immunol. 25:269-289. 
31.  Smith,  D.M., J.A.  Bluestone,  D.R. Jeyarajah, M.H.  New- 
berg, V.H. Engelhard, J.R. Thistlewaite, Jr., and E.S. Woodle. 
1994.  Inhibition of T  cell activation by a monoclonal anti- 
body reactive against the (x3 domain of human MHC class I 
molecules.J. Immunol.  153:1054-1067. 
32.  Tscherning, T.,  and M.H.  Claesson.  1994.  Signal transduc- 
tion via MHC class I molecules in T  cells. Scand. J. Immunol. 
39:117-121. 
33. Brown, J.H., T.S. Jardetzky, J.C. Gorga, L.J. Stern, R.G. Ur- 
ban, J.L.  Strominger, and D.C. Wiley. 1993.  Three-dimen- 
sional structure of the human class II histocompatibility anti- 
gen HLA-DR1. Nature (Lond.). 364:33-39. 
34.  Sloan-Lancaster, J.,  A.S.  Shaw,  J.B.  Rothbard,  and  P.M. 
Allen. 1994.  Partial T  cell signaling: Altered Phospho-~ and 
lack of Zap70  recruitment  in  APL-induced T  cell anergy. 
Cell. 79:913-922. 
35. Madrenas,  J.,  R.L.  Wange,  J.L.  Wang,  N.  Isakov,  L.E. 
Samelson, and R.N. Germain. 1995. ~ phosphorylation with- 
out ZAP-70 activation induced by TCR antagonists or par- 
tial agonists.  Science (Wash.  DC). 267:515-518. 
36. Leuscher, I.F., E. Vivier, A. Layer, J. Mahiou, F. Godeau, B. 
Malissen, and P. Romero.  1995.  CD8 modulation of T-cell 
antigen  receptor-ligand interactions  on  living  cytotoxic  T 
lymphocytes. Nature (Lond.). 373:353-356. 
37. Bjorkman, P.J.,  M.A. Saper, B. Samraoui, W.S. Bennett, J.L. 
Strominger,  and  D.C.  Wiley.  1987.  The  foreign  antigen 
binding site and T  cell recognition regions of class I  histo- 
compatibility antigens. Nature (Lond.). 329:512-518. 
1280  CD8 Interaction with the r  and et3 Domains of MHC Class I 